{"id":1017799,"date":"2026-11-05T11:45:54","date_gmt":"2026-11-05T16:45:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/"},"modified":"2026-11-05T11:45:54","modified_gmt":"2026-11-05T16:45:54","slug":"kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/","title":{"rendered":"Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology<\/b><\/p>\n<p class=\"bwalignc\"><i>Company\u2019s lead candidate ENV-105 has been selected as winner of the Cancer Immunology Solution of the Year Award <\/i><\/p>\n<p>LOS ANGELES&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nKairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fbiotechbreakthroughawards.com%2F&amp;esheet=54635499&amp;newsitemid=20261105422931&amp;lan=en-US&amp;anchor=2026+Biotech+Breakthrough+Awards&amp;index=1&amp;md5=aa026a5f1d5c8541584ecb999805ffac\">2026 Biotech Breakthrough Awards<\/a> in the category of Cancer Immunology Solution of the Year for its work with ENV-105 targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer.<\/p>\n<p>\nKairos Pharma was recognized for its differentiated approach to targeting the biological mechanisms that allow tumors to evade treatment. Rather than developing standalone therapies, Kairos is advancing resistance-modulating treatments designed to restore and extend the effectiveness of existing cancer therapies. At the center of this strategy is ENV-105 (carotuximab), an investigational neutralizing antibody designed to inhibit pathways involved in cancer stem cells and therapy resistance. ENV-105 is being developed in combination with standard-of-care therapies with the goal of improving durability of response across multiple indications.<\/p>\n<p>\n\u201cOur strategy of targeting the mechanisms underlying drug resistance is an important distinction from standard drug development strategy,\u201d said Kairos Pharma Chief Executive Officer Dr. John Yu. \u201cWe owe it to patients facing treatment-resistant disease to not just throw out initially effective treatments when the cancer becomes resistant but to focus on making effective treatments last longer. With ENV-105 and our other pipeline candidates, this novel approach is getting recognized by important third parties like the Biotech Breakthrough Awards, which we believe underscores the potential of this combination approach to address an important unmet need in treatment-resistant cancers.\u201d<\/p>\n<p>\nKairos Pharma <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.kairospharma.com%2Fnews-and-events%2Fnews-releases%2Fnews-details%2F2026%2FKairos-Pharma-Reports-Positive-Statistically-Significant-Interim-Efficacy-Data-from-Phase-2-Trial-of-ENV-105-in-Metastatic-Prostate-Cancer%2Fdefault.aspx&amp;esheet=54635499&amp;newsitemid=20261105422931&amp;lan=en-US&amp;anchor=recently+announced&amp;index=2&amp;md5=a99ca25d51f7f3906e605b9dac683cb4\">recently announced<\/a> positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim analysis demonstrated a statistically significant difference in progression-free survival (PFS) between all patients in the trial treated with ENV-105 plus apalutamide and those treated with apalutamide alone.<\/p>\n<p>\nThe Biotech Breakthrough Awards program recognizes the most innovative companies, technologies, and products in the global life sciences and biotechnology industries. Conducted annually by Biotech Breakthrough, a leading independent market intelligence organization, the awards celebrate excellence across biopharma, therapeutics, genomics, diagnostics, and research tools.<\/p>\n<p><b>About Kairos Pharma Ltd.<\/b><\/p>\n<p>\nBased in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Kairos Pharma\u2019s lead candidate, ENV-105 (carotuximab), is an antibody targeting CD105 \u2014 a protein identified as a key driver of resistance and disease relapse in response to standard cancer therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kairospharma.com&amp;esheet=54635499&amp;newsitemid=20261105422931&amp;lan=en-US&amp;anchor=kairospharma.com&amp;index=3&amp;md5=bca578eb59b0e458e087126611901f1d\">kairospharma.com<\/a>.<\/p>\n<p><b>Cautionary Statement Concerning Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains \u201cforward-looking statements\u201d as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the potential of ENV-105 and the Company\u2019s other product candidates to address drug resistance and improve or extend the effectiveness of existing cancer therapies; the potential benefits and effectiveness of ENV-105 in combination with standard-of-care therapies; the Company\u2019s development plans for ENV-105; and the potential of the Company\u2019s product candidates to address unmet needs in treatment-resistant cancers. Forward-looking statements are identified by terminology such as \u201cmay,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201ccontemplates,\u201d \u201cestimates,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201cprojected,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d or \u201chopes,\u201d or the negative of these or similar terms. Actual results could vary materially from expectations and projections of Kairos Pharma if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize. Risk factors include but are not limited to: success and\/or completion of Phase 2 clinical trials (for prostate cancer) and Phase 1 clinical trials (for lung cancer); the risk that interim clinical trial results may not be predictive of final results; challenges inherent in product research and development; uncertainty regarding future regulatory approval and commercial success; and other factors described in Kairos Pharma\u2019s SEC filings, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Kairos Pharma is not obligated to update any forward-looking statement except as required by applicable law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105422931r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261105422931\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261105422931\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<br \/><\/b>CORE IR | <a rel=\"nofollow\" href=\"mailto:investors@kairospharma.com\">investors@kairospharma.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Stem Cells Biotechnology Research Pharmaceutical Oncology Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology Company\u2019s lead candidate ENV-105 has been selected as winner of the Cancer Immunology Solution of the Year Award LOS ANGELES&#8211;(BUSINESS WIRE)&#8211; Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its work with ENV-105 targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer. Kairos Pharma was recognized for its differentiated approach to targeting the biological mechanisms that allow tumors to evade treatment. Rather than developing standalone therapies, Kairos is advancing resistance-modulating treatments designed to restore and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017799","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology Company\u2019s lead candidate ENV-105 has been selected as winner of the Cancer Immunology Solution of the Year Award LOS ANGELES&#8211;(BUSINESS WIRE)&#8211; Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its work with ENV-105 targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer. Kairos Pharma was recognized for its differentiated approach to targeting the biological mechanisms that allow tumors to evade treatment. Rather than developing standalone therapies, Kairos is advancing resistance-modulating treatments designed to restore and &hellip; Continue reading &quot;Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T16:45:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105422931r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology\",\"datePublished\":\"2026-11-05T16:45:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\\\/\"},\"wordCount\":749,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105422931r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\\\/\",\"name\":\"Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105422931r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-05T16:45:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105422931r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261105422931r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/","og_locale":"en_US","og_type":"article","og_title":"Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology - Market Newsdesk","og_description":"Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology Company\u2019s lead candidate ENV-105 has been selected as winner of the Cancer Immunology Solution of the Year Award LOS ANGELES&#8211;(BUSINESS WIRE)&#8211; Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its work with ENV-105 targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer. Kairos Pharma was recognized for its differentiated approach to targeting the biological mechanisms that allow tumors to evade treatment. Rather than developing standalone therapies, Kairos is advancing resistance-modulating treatments designed to restore and &hellip; Continue reading \"Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T16:45:54+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105422931r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology","datePublished":"2026-11-05T16:45:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/"},"wordCount":749,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105422931r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/","name":"Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105422931r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-05T16:45:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105422931r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261105422931r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kairos-pharma-recognized-by-biotech-breakthrough-awards-in-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017799"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017799\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}